Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE: 600196)
Health Care · Pharmaceuticals · CN
CN¥23.89
-0.54% today · -18.6% 1Y
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE: 600196) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.72B and employs 40,684 people.
Over the last twelve months the share price has lost 18.6%, trading between 20.85 and 30.00.
Tweenvest scores Shanghai Fosun Pharmaceutical (Group) Co., Ltd. across four factors: quality 62/100, value 55/100, growth 53/100, dividend 34/100. Its strongest factor is quality.
600196 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.72B
- Revenue (TTM)
- $6.27B
- P/E
- 18.66
- EPS
- 1.28
- Dividend yield
- 1.63%
- Beta (5Y)
- 0.38
- 52-week high
- CN¥30.00
- 52-week low
- CN¥20.85
- Avg volume (3M)
- —
- Shares outstanding
- 2.64B
- Employees
- 40,684
- Next earnings
- —
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
- ISIN
- CNE000000X38
- Founded
- 1994
- Listed since
- Aug 7, 1998
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Asymchem Laboratories (Tianjin) Co., Ltd.SZSE: 002821 | $9.36B | CN¥177.93 | -5.67% |
| Lupin LimitedBSE: 500257 | $9.26B | Rs1,960.00 | -3.40% |
| Axsome Therapeutics, Inc.NasdaqGM: AXSM | $8.82B | $167.95 | -0.24% |
| Krka, d. d.LJSE: KRKG | $8.76B | €258.50 | +0.78% |
| Financière de Tubize SAENXTBR: TUB | $8.47B | €170.00 | +0.41% |
| Eisai Co., Ltd.TSE: 4523 | $8.19B | ¥4,603.00 | -0.60% |
| ALK-Abelló A/SCPSE: ALK B | $7.56B | Dkr228.00 | +0.26% |
| Kyowa Kirin Co., Ltd.TSE: 4151 | $7.35B | ¥2,222.50 | +0.61% |
Figures last refreshed Oct 11, 2026.